Skip to main content
Canna~Fangled Abstracts

Inhalant cannabidiol impedes tumor growth through decreased tumor stemness and impaired angiogenic switch in NCI-H1437-induced human lung cancer model

By February 3, 2023February 6th, 2023No Comments

. 2023 Feb 3.

doi: 10.1007/s13577-023-00869-8.

Online ahead of print.
Évila Lopes Salles 1 2, Sahar Emami Naeini 1 2, Hesam Khodadadi 3, Bidhan Bhandari 1 2 4, Sholeh Rezaee 5, Edie Threlkeld 5, Hannah M Rogers 6, Vincenzo Costigliola 7, Alvin V Terry Jr 8, David C Hess 3, Sumitra Deb 9 10, Swati Palit Deb 9 10, W Andrew Yeudall 1 2, Jack C Yu 11, Lei P Wang 1 2 12, Babak Baban 13 14 15
Affiliations 

Abstract

Lung cancer remains the most chronic form of cancer and the leading cause of cancer mortality in the world. Despite significant improvements in the treatment of lung cancer, the current therapeutic interventions are only partially effective, necessitating the continued search for better, novel alternative treatments. Angiogenesis and cancer stem cells play a central role in the initiation and propagation of cancers. Tumor angiogenesis is triggered by an angiogenic switch when pro-angiogenic factors exceed anti-angiogenic components. Although many anti-angiogenic agents are used in cancer treatment, there are therapeutic limitations with significant side effects. In recent years, cannabinoids have been investigated extensively for their potential anti-neoplastic effects. Our previous findings showed that cannabidiol (CBD) could impede tumor growth in mouse models of melanoma and glioblastoma. Importantly, CBD has been suggested to possess anti-angiogenic activity. In this study, we tested, for the first time, inhalant CBD in the treatment of heterotopic lung cancer and whether such potential effects could reduce cancer stem cell numbers and inhibit tumor angiogenesis. We implanted NCI H1437 human lung cancer cells in nude mice and treated the mice with inhalant CBD or placebo. The outcomes were measured by tumor size and imaging, as well as by immunohistochemistry and flow cytometric analysis for CD44, VEGF, and P-selectin. Our findings showed that CBD decreased tumor growth rate and suppressed expression of CD44 and the angiogenic factors VEGF and P-selectin. These results suggest, for the first time, that inhalant CBD can impede lung cancer growth by suppressing CD44 and angiogenesis.

Keywords: Angiogenesis, Angiogenic switch, CBD, Cannabidiol, Lung cancer

References

    1. Sharma P, Mehta M, Dhanjal DS, Kaur S, Gupta G, Singh H, Thangavelu L, Rajeshkumar S, Tambuwala M, Bakshi HA, Chellappan DK, Dua K, Satija S. Emerging trends in the novel drug delivery approaches for the treatment of lung cancer. Chem Biol Interact. 2019;25(309): 108720. – DOI
    1. Ragavan M, Patel MI. The evolving landscape of sex-based differences in lung cancer: a distinct disease in women. Eur Respir Rev. 2022;31(163): 210100. – DOI
    1. Li K, Zang X, Meng X, Li Y, Xie Y, Chen X. Targeted delivery of quercetin by biotinylated mixed micelles for non-small cell lung cancer treatment. Drug Deliv. 2022;29(1):970–85. – DOI
    1. Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77(9):1745–70. – DOI
    1. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401–10. – DOI

LinkOut – more resources

Leave a Reply